Drug intelligence / Profile preview

TAK-783 + methotrexate

Development stage: Phase 2
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-783 is an orally administered small molecule drug developed by Takeda for the treatment of rheumatoid arthritis. It has been studied in combination with methotrexate, a standard disease-modifying antirheumatic drug (DMARD), in clinical trials for rheumatoid arthritis. TAK-783 acts as a T helper 1 cell inhibitor, targeting immune pathways involved in the pathogenesis of autoimmune diseases such as rheumatoid arthritis. The combination aims to reduce inflammation and slow disease progression by modulating immune responses[1][2][3].

Targets

DHFR (Dihydrofolate reductase)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)OAT4 (Solute carrier family 22 member 11)

Beyond the preview

Go deeper on TAK-783 + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-783 + methotrexate.